At Investor Conferences

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Asia or involving organisations from these countries.

Total search results: 1283 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Firefly Bio–Decheng Capital: investment, 202402c emerges with financing round Series A totalling $94m incl co-investor Decheng Capital 2024-02-15
Firefly Bio–SEVERAL: investment, 202402c emerges with financing round Series A $94m co-led by Versant Ventures + MPM BioImpact 2024-02-15
Firefly Bio–Versant Ventures: investment, 202402c emerges with financing round Series A totalling $94m incl co-lead investor Versant Venture 2024-02-15
Sysmex–SAFIA Technologies: mycotoxin immunoassays, 202402– distribution ww of tests for food/agri by Sysmex Partec using SAFIA tech + flow cytometry 2024-02-15
BioAge Labs–Nan Fung: investment, 202402 financing round Series D totalling $170m incl new + co-investor Pivotal BioVenture Partners 2024-02-13
BioAge Labs–SEVERAL: investment, 202402 financing round Series D $170m led by Sofinnova Investments 2024-02-13
BioNTech–WuXi PharmaTech: drug discovery services, 202401– supply discovery of MAb candidates $20m upfront + milestones + royalties by WuXi Biologics 2024-01-11
Aiolos Bio–GSK: investment, 202401– acquisition $1b upfront + $400m milestones 2024-01-09
Novartis–Argo Biopharma: RNAi therapeutics, 202401– two license ex-China + collab agreements $185m upfront + $3.98b milestones + royalties 2024-01-07
SanReno Therapeutics–Novartis: investment, 202401 acquisition remaining shares by Novartis to become wholly-owend subsidiary 2024-01-05
Full-Life Technologies–OTHER: credit, 202401– loan facility $16m 2024-01-04
Full-Life Technologies–SEVERAL: investment, 202401 financing round Series B $47.3m led by Prosperity7 Ventures + undisclosed healthcare investor 2024-01-04
Menarini–Insilico Medicine: KAT6 inhibitor, 202401– license ww excl up to >$500m incl $12m upfront + royalties for KAT6A inhibitor to Stemline Tx 2024-01-04
AstraZeneca–Allorion Therapeutics: EGFR inhibitor, 202401– excl option + ww license $40m upfront/near + >$500m milestones + royalties EGFR L858R AI 2024-01-02
Roche–MediLink Therapeutics: antibody-drug conjugates, 202401– collab + ww license for YL211 $50m upfront + near-term + total nearly $1b + royalties 2024-01-02
Gracell Biotechnologies–AstraZeneca: investment, 202312– acquisition $1b upfront cash + $200m milestone-based CVRs 2023-12-26
RayzeBio–BMS: investment, 202312– acquisition cash tender offer $4.1b ($3.6b net of cash) at $62.5/share 2023-12-26
Paion–Humanwell Healthcare: investment, 202312 acquisition of essential business operation of insolvent Paion AG + Paion Deutschland GmbH 2023-12-22
Brinter–UPM: bioink, 202312– distribution of GrowInk bioinks of UPM Biomedicals by Brinter in North America + most of Europe + AU+NZ 2023-12-21
GSK–Hansoh Pharmaceutical: antibody-drug conjugates, 202312– license ww excl Greater China to HS-20093 $185m upfront + $1.525b milestones + royalties 2023-12-20
Shinobi Therapeutics–Astellas: investment, 202312 financing round Series A totalling $51m incl co-investor Astellas Venture Management 2023-12-12
Shinobi Therapeutics–D3 LLC: investment, 202312 financing round Series A totalling $51m incl co-investor D3 LLC 2023-12-12
Shinobi Therapeutics–EQT: investment, 202312 financing round Series A totalling $51m incl co-lead investor EQT Life Sciences 2023-12-12
Shinobi Therapeutics–F-Prime: investment, 202312 financing round Series A totalling $51m incl co-lead investor F-Prime Capital 2023-12-12
Shinobi Therapeutics–Fast Track Initiative: investment, 202312 financing round Series A totalling $51m incl co-investor Fast Track Initiative 2023-12-12
Shinobi Therapeutics–Fidelity: investment, 202312 financing round Series A totalling $51m incl co-lead investor Eight Roads Ventures Japan 2023-12-12
Shinobi Therapeutics–JIC Venture: investment, 202312 financing round Series A totalling $51m incl co-investor JIC Venture Growth Investments 2023-12-12
Shinobi Therapeutics–SEVERAL: investment, 202312 financing round Series A $51m led by EQT LS + F-Prime Capital + Eight Roads Ventures Japan 2023-12-12
Tome Biosciences–Fujifilm: investment, 202312 financing rounds Series A + B totalling $213m incl investor Fujifilm Corp 2023-12-12
Tome Biosciences–SEVERAL: investment, 202312 financing rounds Series A + B $213m announced at launch 2023-12-12
Odyssey Therapeutics–KB Investment: investment, 202312 financing round Series C totalling $101m incl co-investor KB Investment 2023-12-05
Odyssey Therapeutics–SEVERAL: investment, 202312 financing round Series C $101m led by Ascenta Capital 2023-12-05
AstraZeneca–Accenture: clinical research software, 202311– collab to accelerate + expand adoption of Evinova digital products globally 2023-11-20
AstraZeneca–Amazon: clinical research software, 202311– collab with AWS to accelerate + expand adoption of Evinova digital products globally 2023-11-20
Fortrea–AstraZeneca: clinical research software, 202311– strategic collab Fortrea offering Evinova digital health solutions to customers 2023-11-20
Parexel–AstraZeneca: clinical research software, 202311– strategic collab Parexel offering Evinova digital health solutions to customers 2023-11-20
Novartis–GenScript: CAR-T cell therapies, 202311– license excl ww $100m upfront + $1.01b milestones + royalties for DLL CAR-Ts Legend Biotech 2023-11-13
AstraZeneca–Eccogene: GLP-1 receptor agonist, 202311– license ww excl $185m upfront + $1.825b milestones + royalties for ECC5004 2023-11-09
Kynexis–Forbion: investment, 202311 financing round Series A totalling €57m incl co-founding + lead investor Forbion 2023-11-07
Kynexis–SEVERAL: investment, 202311 financing round Series A €57m led by Forbion 2023-11-07
Kynexis–Sunstone Life Science: investment, 202311 financing round Series A totalling €57m incl co-investor Sunstone Life Science Ventures 2023-11-07
Kynexis–Ysios Capital: investment, 202311 financing round Series A totalling €57m incl co-founding + co-investor Ysios Capital 2023-11-07
Argo Biopharma–CS Capital: investment, 202311 financing round Series A+ totalling >$40m incl lead investor CS Capital 2023-11-01
Argo Biopharma–Huagai Capital: investment, 202311 financing round Series A+ totalling >$40m incl new + co-investor Huagai Capital 2023-11-01
Argo Biopharma–OneHealth Haihe Capital: investment, 202311 financing round Series A+ totalling >$40m incl new + co-investor OneHealth Haihe Capital 2023-11-01
Argo Biopharma–SEVERAL: investment, 202311 financing round Series A+ >$40m led by CS Capital 2023-11-01
Argo Biopharma–Trinity Innovation Fund: investment, 202311 financing round Series A+ totalling >$40m incl existing + co-investor TIF 2023-11-01
Kynexis–Mitsubish Chemical: KAT-II inhibitor, 202311c– license excl ww rights to develop + commercialize KYN-5356 from MTPC 2023-11-01
LimFlow–Inari Medical: investment, 202311– acquisition $250m cash upfront at closing + $165m by Inari Medical 2023-11-01
Carlyle–SEVERAL: investment, 202310 final closing $356m of Abingworth Clinical Co-Development Co-Investment Fund (CCD-CIF) 2023-10-30
Merck (DE)–Hengrui: cancer drugs, 202310– strategic alliance €160m upfront + total up to €1.4b license HRS-1167 + option SHR-A1904 ww excl China 2023-10-30
Aiolos Bio–Atlas Venture: investment, 202310 financing round Series A totalling $245m incl co-lead investor Atlas Venture 2023-10-25
Aiolos Bio–Bain Capital: investment, 202310 financing round Series A totalling $245m incl co-lead investor Bain Capital Life Sciences 2023-10-25
Aiolos Bio–Forbion: investment, 202310 financing round Series A totalling $245m incl co-lead investor Forbion 2023-10-25
Aiolos Bio–RA Capital: investment, 202310 financing round Series A totalling $245m incl co-investor RA Capital Management 2023-10-25
Aiolos Bio–Sofinnova: investment, 202310 financing round Series A totalling $245m incl co-lead investor Sofinnova Investments 2023-10-25
Aiolos Bio–SEVERAL: investment, 202310 financing round Series A $245m co-led by Atlas Venture + Bain + Forbion + Sofinnova Investments with RA Capital 2023-10-24
FarmInsect–Minderoo Foundation: investment, 202310 financing round Series A totalling €8m incl new + co-investor MF Strategic Impact Fund 2023-10-23
FarmInsect–SEVERAL: investment, 202310 financing round Series A €8m led by Sandwater 2023-10-23
GSK–Hansoh Pharmaceutical: antibody-drug conjugates, 202310– license ww excl Greater China to HS-20089 $85m upfront + $1.485b milestones + royalties 2023-10-20
Merck (US)–Daiichi Sankyo: antibody-drug conjugates, 202310– collab developm + commerc 3 DXd ADCs ww excl JP $4b upfront + $18b milestones 2023-10-19
BioNTech–MediLink Therapeutics: antibody-drug conjugates, 202310– collab + ww license excl China $70m upfront + $>1b milestones for anti-HER3 ADC 2023-10-12
Japan Tobacco–Max Planck: drug discovery, 202310– collab up to 7 years with Lead Discovery Center + its academic network 2023-10-11
Precede Biosciences–Lilly Asia Ventures: investment, <=202310 financing round Series A incl new + co-lead investor Lilly Asia Ventures 2023-10-05
Precede Biosciences–SEVERAL: investment, <=202310 financing round Series A announced when Precede emerged from stealth with $57m in backing 2023-10-05
Point Biopharma–Lilly: investment, 202310–202312 cash tender offer $1.4b by Lilly at $12.5/share 2023-10-03
Mogrify–SEVERAL: investment, 202310 financing round Series A extension $10m bringing total Series A to $46m led by Astellas VM & Parkwalk Advisors 2023-10-02
Alentis Therapeutics–Kyan Technologies: drug discovery technology, 202309– collab using Optim.AI + PD3D technologies for Claudin-1 expression research 2023-09-29
BioProtect–KB Investment: investment, 202309 financing round totalling $28m incl existing + co-investor KB Investments 2023-09-27
BioProtect–SEVERAL: investment, 202309 financing round $28m led by MVM Partners 2023-09-27
Broken String Biosciences–Tencent: investment, 202309 financing round Series A totalling $15m incl existing + co-investor Tencent 2023-09-18
RayzeBio–PeptiDream: investment, 202309 DIVESTMENT via IPO ./.$20.9m with 1.163m shares sold by PeptiDream at $18/share resulting 2% shareholding 2023-09-14
RayzeBio–SEVERAL: investment, 202309 IPO $336.7m with 16.1m+2.6m new shares at $18/share (excl 1.163m shares sold by PeptiDream) 2023-09-14
Consilium–ICR: investment, 202309 acquisition of Consilium Strategic Communications by ICR 2023-09-12
Grande Bio-tech–Oncgnostics: molecular diagnostics, 202309 – distribution of early cancer detection tests developed by Oncgnostics in ASEAN countries 2023-09-05
Oncgnostics–Grande Bio-tech: investment, 202309 financing round totalling €7-digit incl lead investor Grande Bio-tech Co Ltd with €7-digit investment 2023-09-05
Oncgnostics–SEVERAL: investment, 202309 financing round €7-digit led by Grande Bio-tech Co Ltd + incl bm-t + HTGF 2023-09-05
Paptic–SEVERAL: investment, 202309 financing round Series A €23m led by ECBF + incl Ecolab + Itochu Fibre 2023-09-04
Takara Shuzo–Eppendorf: lab automation equipment, 202308– collab strategic co-marketing agreem automating Takara Bio chemistries on epMotion platforms 2023-08-25
IO Biotech–SEVERAL: investment, 202308 private placement $75m with existing + new investors 2023-08-07
Aiolos Bio–Hengrui: TSLP-antibody, 202308– acquisition ww excl developm + commercialisation rights to AIO-001 outside of Greater China 2023-08-01
BioNTech–Duality Biologics: antibody-drug conjugates, 202308– license excl ww excl China? to develop + manufacture + commercialise DB-1305 2023-08-01
LSX–Informa: investment, 202307 acquisition of LSX by Informa Connect 2023-07-31
Crescendo Biologics–Quan Capital: investment, 202307 financing round totalling $32m incl existing investor Quan Capital 2023-07-24
Crescendo Biologics–SEVERAL: investment, 202307 financing round $32m with new investor Kreos Capital + all major existing investors 2023-07-24
Crescendo Biologics–Takeda: investment, 202307 financing round totalling $32m incl existing investor Takeda 2023-07-24
Mage Biologics–Zeria: investment, 202307– Mage Biologics launches with up to $28m to be invested by Tillotts Pharma + TVM LSI II 2023-07-20
Orange Science–Organomation: sample evaporators, 202307– distribution of nitrogen blowdown evaporator lines of Organimation in JP by Orange Science 2023-07-20
BioNTech–Biotheus: antibody cancer drug, 202307– strategic research collab + ww excl option + license agreement 2023-07-19
BioNTech–Biotheus: antibody cancer drug, 202311– collab + license ww excl ex-Greater China for PM8002 $55m upfront + >$1b milestones + royalties 2023-07-19
Tenpoint Therapeutics–Qiming: investment, 202307 financing round Series A totalling $70m incl existing + co-investor Qiming Venture Partners USA 2023-07-12
Crossbow Therapeutics–Mirae Asset: investment, 202307 financing round Series A totalling $80m incl co-investors Mirae Asset VI + Mirae Asset Capital 2023-07-11
Crossbow Therapeutics–SEVERAL: investment, 202307 financing round Series A $80m led by MPM BioImpact + Pfizer Ventures 2023-07-11
BioNTech–Doer Biologics: biopharmaceuticals, 202308– license ww to use Doer Bio discovery to develop + market biotherapeutics against one target 2023-07-10
Exeliom Biosciences–Crescent Enterprises: investment, 202306 financing round Series A extension totalling €8m incl new + lead investor CE-Ventures 2023-06-30
Exeliom Biosciences–SEVERAL: investment, 202306 financing round Series A extension €8m + final closing at total of €18m 2023-06-30
Astellas–Kate Therapeutics: gene therapy, 202306– license excl €na to KT430 gene therapy for XLMTM from KateTx 2023-06-08
Kate Therapeutics–SEVERAL: investment, 202306 financing round Series A $51m co-led Westlake Village BioPartners + Versant Ventures 2023-06-08
Upstream Bio–SEVERAL: investment, 202306 financing round Series B $200m co-led by Enavate Sciences + Venrock Healthcare Capital Partners 2023-06-08
ITM–SEVERAL: investment, 202306 financing round €255m led by Temasek 2023-06-05
1 2 3 4 5 6 7 8 9 10 11 12 13  next pagenext page



Advertisement

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px

» top